These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28975114)

  • 21. Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.
    Okutur K; Bassulu N; Dalar L; Aydin K; Bozkurt M; Pilanci KN; Dogusoy GB; Tecimer C; Mandel NM; Demir G
    Asian Pac J Cancer Prev; 2015; 16(7):2645-51. PubMed ID: 25854340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.
    Citi V; Del Re M; Martelli A; Calderone V; Breschi MC; Danesi R
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):745-754. PubMed ID: 29476223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study.
    Gong C; Zhao Y; Wang B; Hu X; Wang Z; Zhang J; Zhang S
    Oncotarget; 2017 Aug; 8(35):59810-59822. PubMed ID: 28938684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
    Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
    Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.
    Decker T; Marschner N; Muendlein A; Welt A; Hagen V; Rauh J; Schröder H; Jaehnig P; Potthoff K; Lerchenmüller C
    Breast Cancer Res Treat; 2019 Aug; 176(3):637-647. PubMed ID: 31115844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.
    Geiger JL; Bauman JE; Gibson MK; Gooding WE; Varadarajan P; Kotsakis A; Martin D; Gutkind JS; Hedberg ML; Grandis JR; Argiris A
    Head Neck; 2016 Dec; 38(12):1759-1764. PubMed ID: 27232378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I Trial of Everolimus and Capecitabine in Metastatic HER2
    Vidal GA; Chen M; Sheth S; Svahn T; Guardino E
    Clin Breast Cancer; 2017 Oct; 17(6):418-426. PubMed ID: 28385537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.
    Wahl M; Chang SM; Phillips JJ; Molinaro AM; Costello JF; Mazor T; Alexandrescu S; Lupo JM; Nelson SJ; Berger M; Prados M; Taylor JW; Butowski N; Clarke JL; Haas-Kogan D
    Cancer; 2017 Dec; 123(23):4631-4639. PubMed ID: 28759109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
    Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
    Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The drug of the month: everolimus (Afinitor) for the treatment of metastatic breast cancer].
    Jerusalem G; Rorive A; Collignon J
    Rev Med Liege; 2014 Sep; 69(9):510-7. PubMed ID: 25796760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.
    Li N; Hao Y; Xie J; Lin PL; Koo V; Ohashi E; Wu EQ
    Int J Breast Cancer; 2015; 2015():240750. PubMed ID: 26078883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
    Rathkopf DE; Larson SM; Anand A; Morris MJ; Slovin SF; Shaffer DR; Heller G; Carver B; Rosen N; Scher HI
    Cancer; 2015 Nov; 121(21):3853-61. PubMed ID: 26178426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety.
    Riccardi F; Colantuoni G; Diana A; Mocerino C; Cartenì G; Lauria R; Febbraro A; Nuzzo F; Addeo R; Marano O; Incoronato P; De Placido S; Ciardiello F; Orditura M
    Mol Clin Oncol; 2018 Sep; 9(3):255-263. PubMed ID: 30155246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.
    Qiao L; Liang Y; Mira RR; Lu Y; Gu J; Zheng Q
    Int J Clin Exp Med; 2014; 7(10):3333-43. PubMed ID: 25419366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
    Weigelt B; Warne PH; Downward J
    Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
    Massarelli E; Lin H; Ginsberg LE; Tran HT; Lee JJ; Canales JR; Williams MD; Blumenschein GR; Lu C; Heymach JV; Kies MS; Papadimitrakopoulou V
    Ann Oncol; 2015 Jul; 26(7):1476-80. PubMed ID: 26025965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
    Campone M; Bachelot T; Gnant M; Deleu I; Rugo HS; Pistilli B; Noguchi S; Shtivelband M; Pritchard KI; Provencher L; Burris HA; Hart L; Melichar B; Hortobagyi GN; Arena F; Baselga J; Panneerselvam A; Héniquez A; El-Hashimyt M; Taran T; Sahmoud T; Piccart M
    Eur J Cancer; 2013 Aug; 49(12):2621-32. PubMed ID: 23735704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The regulatory role of aberrant Phosphatase and Tensin Homologue and Liver Kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors.
    Chang TM; Shan YS; Chu PY; Jiang SS; Hung WC; Chen YL; Tu HC; Lin HY; Tsai HJ; Chen LT
    Oncotarget; 2017 Nov; 8(58):98068-98083. PubMed ID: 29228674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.
    Gao X; Jegede O; Gray C; Catalano PJ; Novak J; Kwiatkowski DJ; McKay RR; George DJ; Choueiri TK; McDermott DF; Signoretti S; Bhatt RS
    Clin Genitourin Cancer; 2018 Oct; 16(5):341-348. PubMed ID: 29754934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.